In agreement with this, recent studies have demonstratedthat inhibition of the Rho family protein with the selective Rho inhibitorstipifarnib or fasudil is capable of attenuating ventricular remodeling (83) and preventing development ofhypoxia-induced PAH (84). This evidence concerns the gene RHO and pulmonary arterial hypertension.